A Review of Adverse Events From the Use of Diphtheria Antitoxin (DAT) in the United States, 2004-2019
- PMID: 34628502
- PMCID: PMC9276519
- DOI: 10.1093/cid/ciab899
A Review of Adverse Events From the Use of Diphtheria Antitoxin (DAT) in the United States, 2004-2019
Conflict of interest statement
Comment on
-
Diphtheria Antitoxin Administration, Outcomes, and Safety: Response to a Diphtheria Outbreak in Cox's Bazar, Bangladesh.Clin Infect Dis. 2021 Oct 5;73(7):e1713-e1718. doi: 10.1093/cid/ciaa1718. Clin Infect Dis. 2021. PMID: 33245364 Free PMC article.
References
-
- Centers for Disease Control and Prevention. Availability of diphtheria antitoxin through an investigational new drug protocol. MMWR Morb Mortal Wkly Rep 1997; 46:380. - PubMed
-
- Centers for Disease Control and Prevention. Expanded access investigational drug (IND) application protocol: use of diphtheria antitoxin (DAT) for suspected diphtheria cases. 2020.
-
- Vargha D, Greene JA. Grey-market medicines: diphtheria antitoxin and the decay of biomedical infrastructure. Lancet 2017; 389:1690–1.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
